Create Account

One Health helps you track and understand your health simply.

Create Account

One Health helps you track and understand your health simply.

Factor X Preliminary

Coagulation

F10 activityFactor X activityFX activityStuart-Prower factor activity

Review status

Currently under review

Pending specialist review and validation.

What it shows

The Factor X Preliminary test is a screening assay that estimates how well factor X, a clotting protein, is working in your blood. Factor X is made in the liver and depends on vitamin K. It plays a central role in turning on thrombin, which helps your blood form stable clots.

This preliminary result provides a quick look at factor X activity to help your care team decide whether further, more specialized testing is needed. If results point to a problem, your clinician may order confirmatory assays or studies to look for inhibitors or other causes.

Why it matters

Your clinician may order this test if you have unusual bleeding, easy bruising, bleeding after procedures, or an unexplained change in clotting tests such as the prothrombin time or INR. It helps evaluate for inherited factor X deficiency and common acquired causes like vitamin K deficiency, liver disease, or the effect of anticoagulant medicines.

Results can guide treatment decisions, such as giving vitamin K, adjusting medications, or investigating liver health. It can also help identify rare conditions, including acquired factor X deficiency related to systemic diseases, so that care can be tailored to your situation.

Understanding your results

If your factor X activity is lower than expected, it may reflect an inherited deficiency, a vitamin K problem, liver dysfunction, the effect of certain medications, or an inhibitor that interferes with the assay. Your clinician may repeat the test, review your medications and nutrition, check other clotting factors and liver tests, or order a mixing study or specific confirmatory assays.

If activity appears higher than expected, it is usually not concerning by itself and can be seen with inflammation or during pregnancy. Your results will be interpreted alongside other tests and your symptoms. If anything is unclear, your care team may retest or use a different method to confirm the finding and decide on next steps.

Reference ranges

0.451.5 U/mL
All sexes
0 days – 1 month
0.51.5 U/mL
All sexes
1 month – 150 years

Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.

Factors that could impact Factor X Preliminary

  • Blood thinners and other drugs

    Warfarin and other anticoagulants can lower measured activity or interfere with the assay. Some direct oral anticoagulants and heparin may affect certain reagents. Always tell your clinician about all medications and supplements.

  • Vitamin K status and nutrition

    Low vitamin K intake, poor absorption, or recent broad‑spectrum antibiotics can reduce factor X production. Your clinician may consider diet, supplements, and gut health when interpreting this test.

  • Liver health and systemic illness

    Factor X is made in the liver, so liver disease can reduce levels. Severe infections, disseminated intravascular coagulation, or amyloidosis can also affect factor X and may require additional evaluation.

  • Sample collection and handling

    Improper tube fill, delayed processing, incorrect citrate ratio, or high hematocrit can distort results. Drawing the sample away from an infusion line and timely processing help ensure accuracy.

  • Age and pregnancy

    Newborns can have naturally lower factor activity, which rises with maturation. During pregnancy, some clotting factors may increase. Your clinician will interpret results using the appropriate context.

2026

References

  1. McGill University Health Centre. (2016, March 17). Factor X Preliminary (Task CD 18461587). Laboratory reference ranges.
  2. Mumford, A. D., Ackroyd, S., Alikhan, R., Grainger, J., Laffan, M., et al. (2020). Guideline for the diagnosis and management of rare coagulation disorders. British Journal of Haematology.
  3. Clinical and Laboratory Standards Institute. (2008). Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays; Approved guideline (5th ed., CLSI document H21-A5).